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Introduction
Migraine is equally common in both genders until puber-
ty, when it becomes approximately three times more
prevalent in women than in men [1, 2]. This greater preva-
lence in women is due, in part, to the influence of female
sexual hormones. More than 50% of women relate a peri-
odicity of their migraine attacks to their menstrual cycles
[3, 4], although in most cases they also have migraine
attacks outside the menstrual period. It has been proposed
that menstrual migraine is due to oestrogen withdrawal in
the late luteal phase of the normal menstrual cycle acting
as a migraine trigger in predisposed individuals [5], but
other factors such as prostaglandin release have also been
implicated [6]. However, the true prevalence of menstrual
migraine attacks (those occurring during the peri-men-
strual period) is unclear due to retrospective reports and
variable definitions of menstrual migraine [7].
Menstrual migraine attacks are treated with standard
acute therapies and with specific prophylactic treatments
such as oestrogen supplements taken during the peri-men-
strual period [6]. It has been widely considered that men-
strual migraine attacks are more severe and less responsive
to drug treatments and non-pharmacological approaches
than non-menstrual attacks [6, 8], but the data to support this
J Headache Pain (2005) 6:81–87
DOI 10.1007/s10194-005-0156-3
Managing migraine headaches experienced by
patients who self-report with menstrually
related migraine: a prospective,
placebo-controlled study with oral sumatriptan
O R I G I N A L
A.J. Dowson ()
The King’s Headache Service,
King’s College Hospital,















Abstract The objective was to
evaluate the efficacy and tolerabili-
ty of oral sumatriptan (100 mg) in
patients who self-reported with




study was carried out in 20 UK pri-
mary and secondary care surgeries.
Of 115 patients with a self-reported
history of menstrually related
migraine that entered the study, 93
patients completed it. Patients treat-
ed all migraine attacks for 2 months
with sumatriptan (100 mg) and for
2 months with placebo. The prima-
ry endpoint was the proportion of
patients reporting headache relief at
4 hours for the first treated attack.
Only 11% of patients fulfilled the
protocol definition of menstrually
related migraine. Patients reported a
variable pattern of migraine attacks
occurring inside and outside the
menstrual window. For the first
attack, significantly more patients
receiving sumatriptan than placebo
reported headache relief for attacks
occurring inside (67% vs. 33%,
p=0.007) and outside (79% vs.
31%, p<0.001) the menstrual peri-
od. Sumatriptan was generally well
tolerated. Oral sumatriptan (100
mg) is an effective and well tolerat-
ed acute treatment for patients who
report menstrually related migraine.
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proposition are somewhat equivocal. Population- and case-
based studies have indicated that attacks of migraine at the
time of menstruation are more severe, of longer duration and
more resistant to treatment than attacks at other times of the
month [9–11]. A small study with sumatriptan indicated that
the drug was less effective for attacks occurring during men-
struation than for those occurring at other times (56% vs.
81% of patients reporting relief of their migraine headache
4 hours after treatment, when treated during and outside the
menstrual period, respectively) [12]. On the other hand, a
population-based epidemiological study indicated that men-
strually associated migraine attacks were slightly more
painful, but not more disabling, than attacks occurring at
other times in the cycle [13]. Also, a recent study has indi-
cated that migraine attacks occurring outside the menstrual
period were more disabling to the sufferer than those occur-
ring during the menstrual period [14].
The triptans are selective 5-hydroxytryptamine 1 (5-
HT1B/1D) receptor agonists, which have been shown to be
effective for the acute treatment of migraine [15]. The
subcutaneous formulation of sumatriptan [16, 17] and oral
formulations of zolmitriptan [18], rizatriptan [19, 20] and
eletriptan [21] were shown to be effective treatments for
menstrual migraine attacks. However, these studies gener-
ally relied on a retrospective diagnosis of menstrual mi-
graine, and assessed the efficacy of the triptan on migraine
attacks occurring only at the time of menstruation. What
these studies have not investigated is the distribution of
migraine attacks inside and outside the menstrual period
for patients reporting with menstrual migraine and the
clinical profile of the triptans in the spectrum of migraine
attacks experienced by these patients.
This study assessed the efficacy of oral sumatriptan (100
mg) on migraine attacks experienced over four menstrual
cycles by a group of patients who self-reported with menstru-
ally related migraine. The relationship between migraine
attacks and menstruation was collected prospectively, and the
study therefore provided an opportunity to re-examine the
clinical relevance of the definitions of menstrually related
migraine. This study was prospective in design, unlike many
other studies conducted with triptans in menstrual migraine.
Patients and methods
Patients
All patients were women aged between 18 and 50 years who
self-reported to the investigator with menstrually related
migraine (based on patient recall of having experienced a men-
strually related migraine attack in two of their last three men-
strual cycles and >80% of their attacks falling within the men-
strual window in the previous 6 months). Patients presented with
a history of one to four moderate or severe migraine attacks with
or without aura per month (in accordance with the International
Headache Society [IHS] diagnostic criteria pertaining at the
time) [22]. The majority of attacks (at least 80%) were reported
to occur during the menstrual window (the 8 days starting 3 days
before the onset of menstruation). Prophylactic migraine therapy
and hormonal therapy were kept constant for 3 and 6 months,
respectively, prior to the study and throughout the study. Patients
were excluded from the study if they were pregnant or likely to
become pregnant during the study, were lactating, or had hyper-
tension (supine diastolic pressure >95 mmHg), ischaemic heart
disease, atherosclerotic disease or other concurrent medical con-
ditions that could affect the study data or for which there was a
medical contraindication. Patients were also excluded if they
were regularly taking analgesics, anti-emetics or anti-hista-
mines, abused ergotamine or alcohol, or had a hypersensitivity
to, intolerance of, or contraindication to the use of sumatriptan.
Methods
Study design
This was a multicentre, randomised, double-blind, placebo-con-
trolled, crossover design study conducted in 20 primary and sec-
ondary care (neurology and gynaecology clinics) centres in the
United Kingdom. The study (Protocol Number GL-MIG-017)
was conducted in accordance with the Declaration of Helsinki
and Good Clinical Practice, primarily through hospital out-
patient clinics. Each centre obtained Local Ethics Committee
approval before starting the study and all patients gave their
written informed consent to participate.
Treatments
Patients were randomised to one of two treatment groups: Group 1
received oral sumatriptan (100 mg) for two menstrual cycles fol-
lowed by placebo for two menstrual cycles; Group 2 received
placebo followed by sumatriptan (100 mg). Patients treated all
their migraine attacks of moderate or severe intensity over the four
menstrual periods with study medication. Patients could take up to
three sumatriptan 100 mg or placebo tablets in any 24-hour period,
if the migraine improved but then returned (headache recurrence),
providing a minimum of 4 hours elapsed between the doses. If
symptoms were not adequately relieved at 4 hours after the first
dose, patients could take rescue medication (excluding commer-
cially available sumatriptan or ergotamine-containing medications;
other triptans were not available at the time of the study).
Patients recorded on diary cards details of their migraine
attacks before treatment and the subsequent response to study
medication. Headache severity was rated on a four-point scale:
no pain (Grade 0), mild pain (Grade 1), moderate pain (Grade 2)
or severe pain (Grade 3). Patients also completed calendar cards
to indicate the days on which their menstruation occurred.
Patients visited the clinic each month for assessment of their
progress and the recording of adverse events.
Endpoints
The primary study efficacy endpoints were the proportions of
patients who reported headache relief (a reduction in headache
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severity from severe or moderate [Grade 3/2] to mild or none
[Grade 1/0]), complete headache relief [Grade 3/2 to Grade 0],
any improvement in headache pain [improvement by at least one
grade] and complete improvement of headache pain [Grade
1/2/3 to 0], even though patients treating mild [Grade 1] pain
could be considered as protocol violators) at 4 hours after taking
the first dose of study medication. At the time of this study, the
2-hour time period had not been established as the optimal
timescale to record efficacy in migraine studies. A comparison
was made of the efficacy of sumatriptan between the sub-set of
attacks that commenced inside and outside the menstrual win-
dow. Secondary efficacy endpoints included global assessments
of the efficacy of treatment, assessed by the patients at the end
of each phase of the study as ‘excellent’, ‘good’, ‘moderate’,
‘poor’ or ‘very poor’. Patients also expressed their preference
for the study medication at the end of the study. Tolerability was
assessed in terms of adverse events reported following treatment
with sumatriptan (100 mg) or placebo.
Statistical analysis
Descriptive statistics were calculated for demographic and
migraine history data. Data from the first treated attack in each
phase of the study formed the basis of the primary efficacy
analysis in the intent-to-treat population, as some patients did
not treat more than one attack in each phase. The study was
powered to demonstrate a significant difference between suma-
triptan and placebo. Using large-scale sample theory, a total of
76 evaluable patients were calculated to provide a 90% proba-
bility of a result significant at the 1% level (two-tailed). The
response to treatment was analysed as a standard two-phase
crossover trial with binary data. Estimates of true treatment
success rates were derived using a log-linear model [23]. The
exact p-value was calculated from Prescott’s test. When allow-
ing for the effect of menstrual association, a log-linear model
was used to derive the estimates of treatment effect in each stra-
tum, and an exact p-value as calculated from Prescott’s test,
stratified for menstrual association. Consistency of treatment
effect across the strata was assessed from the patients with dif-
ferent responses in the two phases, using the Zelen test [24]. All
comparisons between the treatments were made only after con-
firmation that there was no evidence to suggest a treatment-by-
phase interaction, i.e., a carryover difference from one cros-
sover phase to the other. Identical methods were used to analyse
the patients’ global assessments of efficacy. A 5% two-tailed
significance level was used throughout the study. Tolerability
was recorded as descriptive statistics in terms of the number of
adverse events and the number and proportion of patients
reporting adverse events.
Results
Patient disposition and demography
A total of 115 patients took part in the study, 110 of whom
treated at least one migraine attack. Sixty-one patients
were randomised to receive sumatriptan for the first phase
and placebo for the second phase (Group 1) and 54 were
randomised to placebo followed by sumatriptan (Group
2). Ninety-three patients completed the study and 22 with-
drew during the study. Reasons given for withdrawal
included patients’ request (11 patients), adverse events (8
patients), failure to return (8 patients), violation of inclu-
sion and/or exclusion criteria (4 patients), lack of efficacy
(3 patients) and other reasons (4 patients). Many of the
patients gave more than one reason for their withdrawal.
Demographic data and baseline characteristics of the
study population are shown in Table 1, and were similar
for the two groups. For the whole study population, the
Table 1 Patient demography and migraine history: denominator figures, 61 (Group 1) and 54 (Group 2), except where indicated
Group 1 (n=61) Group 2 (n=54) All patients (n=115)
Mean age, years (range) 37 (19–49) 40 (19–50) 38 (19–50)
Race, n (%)
Caucasian 59 (97) 53 (98) 112 (97)
Asian 2 (3) 1 (2) 3 (3)
Migraine history, years (range) 14 (1–40) 16 (1–40) 15 (1–40)
Migraine type, n (%)
With aura 1 (2) 0 (0) 1 (1)
Without aura 25 (41) 33 (61) 58 (50)
With and without aura 35 (57) 21 (39) 56 (49)
Average duration of attacks ≥1 day, n (%) 55/58 (95) 52/53 (98) 107/111 (96)
Patients using:
Acute medications, n (%) 42 (69) 46 (85) 88 (77)
Prophylactic medications, n (%) 9 (15) 8 (15) 17 (15)
Hormone-base therapy, n (%) 10 (16) 14 (26) 24 (21)
Patients reporting usual acute treatment good/excellent, n (%) 17/57 (30) 10/52 (19) 27/109 (25)
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mean age was 38 years (range 19–50 years) and all but
three patients (who were Asian) were Caucasian. Patients
had a mean migraine history of 15 years, with 50% suf-
fering only from migraine without aura and 49% from
migraine with and without aura. One patient reported
only attacks of migraine with aura. Almost all patients
(96%) reported a history of migraines of long duration,
lasting ‘one day’ or ‘several days’, even when treated
with their usual migraine medication. Most patients
(77%) used acute medications, but relatively few used
prophylactic medications (15%) or hormone-based thera-
py (21%) in the month before the study started. The spe-
cific prophylactic medications and hormone therapies
were not recorded for the patients. However, only 25% of
patients rated their usual acute medication as ‘excellent’
or ‘good’ at entry into the study. The patients entering this
study self-reported with menstrually related migraine
(defined in the study protocol as ≥80% of migraine
attacks occurring during the menstrual window in the
previous 6 months).
Distribution of attacks inside and outside the menstrual
window
The median of the mean number of attacks suffered by
patients during the study was 2.5 per month. During the
study, patients recorded when migraine attacks and men-
struation occurred. This information was used to cate-
gorise attacks as either inside or outside the menstrual
window. This prospective data was used to check the re-
porting of menstrually related migraine given by each
patient at the study outset. Thirteen patients could not be
classified, leaving 102 patients to be analysed. When the
patients’ migraine attacks were compared with their men-
strual cycles during the study, only 6% of the patients ful-
filled the criteria for pure menstrual migraine (100% of
attacks in the menstrual window) and 11% met the study
criteria for menstrually related migraine (≥80% of attacks
within the menstrual window). Fifty-two per cent of
patients had ≥50% of their migraine attacks within the
menstrual window (Table 2). No noteworthy pattern was
seen in the distribution of the attacks that occurred outside
the menstrual window.
Efficacy
Owing to the small number of patients with pure men-
strual migraine and protocol-defined menstrually related
migraine, efficacy analyses were conducted for the whole
study sample. The efficacy of sumatriptan (100 mg) com-
pared with placebo was analysed for the first migraine
attack treated for patients who completed both phases of
the study. These efficacy analyses were also conducted
on patients who treated at least one migraine attack
occurring inside or outside the menstrual window in each
treatment phase. Significantly more patients receiving
sumatriptan (100 mg) than placebo reported headache
relief, complete headache relief, headache improvement
by at least one grade and complete headache improve-
ment at 4 hours after treatment for migraine attacks
occurring both inside and outside the menstrual window
(Table 3). Results were similar for attacks occurring
inside and outside the menstrual window for all analyses,
although relief rates were slightly higher for attacks tak-
ing place outside the menstrual period. For all the attacks
treated with sumatriptan, headache relief was reported at
4 hours for 80% of attacks occurring outside the men-
strual window and 76% of attacks occurring inside the
menstrual window.
Patients assessed the efficacy of the treatment they
received at the end of each treatment phase. Overall, sig-
nificantly more patients rated sumatriptan (100 mg) than
placebo as ‘good’ or ‘excellent’ (64% vs. 21%, p<0.0001).
At the end of the study, patients stated the treatment they
preferred. Sixty-four per cent of patients preferred suma-
triptan, 15% preferred placebo and 21% expressed no
preference. Of those who expressed a preference, 81%
preferred sumatriptan.
Table 2 Distribution of patients’ migraine attacks inside and outside the menstrual window (8 days commencing 3 days prior to the onset
of menstruation) during the study: denominator figure=102 patients
% attacks occurring within Number of patients (%)
the menstrual window
Patients fulfilling criteria Patients not fulfilling criteria
100 6 (6) 96 (94)
≥80 11 (11) 91 (89)
≥50 53 (52) 49 (48)
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Safety
Eighty-three patients (72%) reported 368 adverse events
during the study. More patients reported adverse events
when they were receiving sumatriptan (100 mg) (64%)
than when they were receiving placebo (44%). The most
common types of adverse event were associated with the
nervous and digestive systems. However, only 8 patients
(7%) withdrew due to adverse events.
Discussion
This study provides evidence for two issues that are clin-
ically relevant for the management of migraine in the clin-
ic. Firstly, pure menstrual migraine, and menstrually
related migraine were found to occur in fewer patients
than originally thought. Secondly, oral sumatriptan (100
mg) is an effective and well tolerated acute treatment for
the spectrum of menstrual migraines and menstrually
associated migraines experienced by patients.
In the present study, patients were recruited who had a
self-reported history of menstrually related migraine, with
a definition of ≥80% of their attacks occurring during their
menstrual periods for the previous 6 months. The average
migraine history was 15 years, with the vast majority of
attacks lasting for 1 day or more. Although most patients
were using acute medications, the majority did not find
them effective. During the study, patients reported frequent
migraine attacks (average 2.5 per month).
During the prospective reporting of migraine attacks
during the study, only 11% of patients reported a pattern of
menstrually related migraine as defined in the study proto-
col. Three groups of patients could be identified from the
diary cards: a small group (11%) who had menstrually
related migraine; a larger group (41%) who showed a con-
sistent pattern of clustering of migraine attacks within the
menstrual window but who had many attacks at other times
in the menstrual cycle; and the largest group (48%) who
had the majority of their attacks outside the menstrual peri-
od. It is clear that there is a considerable and variable
group of women in whom there is a clinically relevant
association between menstruation and migraine attacks.
The clinical profile of these patients may be complex, with
multiple triggers acting in combination.
The over-reporting by patients of a link between men-
struation and migraine has been noted previously.
Definitions for pure and menstrually-related migraine
were proposed of 100% and ≥80% of attacks, respective-
ly, both during the period from −2 to +3 days from the
onset of menstruation [6, 25]. Prospectively collected data
from the present study indicate that a self-reported associ-
ation of migraine attacks with menstruation covers a spec-
trum of illness, from patients with attacks solely associat-
ed with the menstrual period (pure menstrual migraine), to
menstrually related migraine, to those with attacks that
occur primarily outside, but with a few attacks occurring
within the menstrual period. Support for this comes from
two separate sources. Firstly, several studies have indicat-
ed that menstruating women experience migraine attacks
both inside and outside the menstrual period [10, 11, 14].
Secondly, recent studies have demonstrated that severely
affected migraine sufferers have multiple clinical presen-
tations of their migraine attacks, from true migraine,
through migrainous headache to tension-type headache.
Table 3 Efficacy of sumatriptan (100 mg) and placebo in treating migraine attacks occurring inside and outside the menstrual window:
proportion of patients reporting headache relief, complete headache relief, headache improvement and complete headache improvement.
Patients who treated their first attack in the two phases of the study with sumatriptan and placebo
Endpoint Percentage of patients
Inside menstrual window Outside menstrual window
Sumatriptan 100 mg Placebo p-value Sumatriptan 100 mg Placebo p-value
Headache relief 67 (n=39) 33 (n=39) 0.0072 79 (n=41) 31 (n=41) <0.0001
(Grade 3/2 to Grade 1/0)
Complete headache relief 49 (n=39) 10 (n=39) 0.0001 60 (n=41) 9 (n=41) <0.0001
(Grade 3/2 to Grade 0)
Headache improvement 71 (n=48) 33 (n=48) 0.0003 77 (n=48) 33 (n=48) 0.0001
(≥1 grade)
Complete headache improvement 54 (n=48) 15 (n=48) <0.0001 60 (n=48) 21 (n=48) 0.0009
(Grade 1/2/3 to Grade 0)
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However, this entire spectrum of headache may be a man-
ifestation of the migraine process [26].
Data from the present study showed that oral suma-
triptan (100 mg) was an effective and well tolerated acute
treatment for patients with migraine attacks occurring
inside and outside the menstrual period. The proportions
of patients reporting headache relief, complete headache
relief, headache improvement and complete headache
improvement were slightly less for attacks occurring in-
side the menstrual period than for those occurring outside
the period. However, in all cases, sumatriptan (100 mg)
was significantly more effective than placebo and the
response rates were similar to those described previously
for this regimen of the drug [27]. The 4-hour endpoint
was used because the 2-hour time period had not been
established as optimal to record efficacy in migraine
studies at the time of the study. Sumatriptan (100 mg)
was generally well tolerated. The incidence of reported
adverse events was relatively high for both sumatriptan
and placebo, and may indicate a generally poor level of
health and quality of life in these patients due to pre-men-
strual symptoms and frequent migraine attacks. Most pre-
vious studies of triptans in menstrual migraine have eval-
uated their efficacy in treating attacks occurring only
inside the menstrual period [16–21]. The present study
demonstrated the efficacy of oral sumatriptan (100 mg)
for the spectrum of migraine attacks in a population of
patients self-reporting with menstrually related migraine.
To support this, recent studies have shown that oral suma-
triptan (50 mg) is an effective treatment for the spectrum
of headaches reported by the general population of
migraine sufferers [26].
This study does have several limitations. The defini-
tion of menstrually related migraine (self-report of >80%
of menstrual attacks falling within the menstrual window
in the previous 6 months) is questionable and, perhaps not
surprisingly, only a few women (11%) fulfilled this crite-
rion in the prospective study. The latest criterion pub-
lished by the IHS for menstrually related migraine without
aura is: “attacks occur on day 1±2 of menstruation in at
least two out of three menstrual cycles and additionally at
other times of the cycle” [28]. MacGregor’s criterion is
similar, from –2 to +3 days with respect to the first day of
bleeding [6, 25]. From this, the most used criterion to
define menstrually related migraine may be the constant
or almost constant occurrence of menstrual attacks,
regardless of the number of non-menstrual attacks. The
menstrual window used in this study (8 days) may be large
enough to include attacks pathophysiologically and per-
haps clinically different from true menstrual attacks.
Despite these caveats, the study demonstrated a disparity
between what the patients subjectively reported and the
data that were collected prospectively.
In this study, a high percentage of women (49%) suf-
fered from migraine with and without aura. Classically,
menstrually related migraine is without aura, as defined by
the IHS [28]. The high prevalence of women suffering
from migraine with aura in this study may have affected
the results. Finally, the primary study time point for assess-
ment (4 hours) is not currently used in migraine studies, 2
hours being regarded as the optimal time point [29].
Clinical implications
Further studies are necessary to explore the treatment of
migraine headaches occurring inside and outside the men-
strual period. However, some general principles can be
proposed. Migraine is a disabling condition, irrespective
of its time of onset [30]. Where patients have migraine
attacks that occur both inside and outside the menstrual
period, they can probably be managed using standard acu-
te therapies (e.g., triptans and analgesic plus anti-emetic
combinations). Both oral and subcutaneous sumatriptan
formulations provide effective treatment, although the
maximal oral dose of sumatriptan was used in the present
study. The efficacy of lower oral doses of sumatriptan (50
mg and 25 mg) is not known, but may be less than that
reported here for the 100 mg dose in this group of patients
[31]. Oestrogen supplements may be best reserved for
patients with migraine attacks that occur during menstru-
ation only (pure menstrual migraine).
In conclusion, most women who self-report menstrual-
ly related migraine do not have the condition, but experi-
ence a spectrum of migraine attacks both inside and out-
side their menstrual periods. Oral sumatriptan (100 mg) is
an effective and well tolerated acute treatment for all the
migraine attacks experienced by these patients.
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